Seiji Wakao
JPMorgan Chase & Co, Research Division
Good afternoon. Welcome to JPMorgan Healthcare Conference. This is Seiji Wakao, Japanese Pharmaceutical Health Care Analyst. It’s my pleasure to introduce Okuzawa-san, CEO of Daiichi Sankyo. Welcome to him conference. Please go ahead.
Hiroyuki Okuzawa
President, CEO & Representative Director
Thank you, Wakao-san. Hello, colleagues. I appreciate your interest in Daiichi Sankyo. I would like to express my sincere gratitude to JPMorgan for providing the opportunity to present at this remarkable conference today. My name Hiroyuki Okuzawa and I have taken on the role of CEO at Daiichi Sankyo since April 2025. It is a privilege to stand before you today and share our vision and progress as we strive to contribute to enrichment of quality of life around the world.
First, I will start with a brief overview of Daiichi Sankyo. Next, I will introduce you to our ADCs, focusing on our DXd-ADC technology that is currently the main driver of our company’s growth led by ENHERTU and DATROWAY. Following that, I will talk about our Science and Technology, focusing on our exciting new multi-modality strategy. Finally, I will conclude with our shareholder return policy and our strong commitment to enhancing shareholder value.
With that road map in mind, let’s begin with the first part, the overview of Daiichi Sankyo. Daiichi Sankyo is a global pharmaceutical company headquartered in Tokyo, Japan. For the current fiscal year ending March 31, 2026, we expect revenue of approximately JPY 2.1 trillion, an increase of 11% from the previous fiscal year. Our forecast for core operating
